Biogen’s felzartamab has been approved in China as a treatment [...]

Poolbeg Pharma’s Phase 2a TOPICAL trial is investigating whether POLB [...]

Poolbeg Pharma has dosed the first patient in a clinical [...]

Poolbeg Pharma has received a decision to grant a European [...]

Poolbeg Pharma has activated the first clinical site and begun [...]

The Scottish Medicines Consortium (SMC) has accepted TALVEY (talquetamab) for [...]

Quest Diagnostics has introduced a new blood-based test for measurable [...]

The National Institute for Health and Care Excellence (NICE) has [...]

Heidelberg Pharma has reported further clinical activity from its Phase [...]

CytoAgents, a clinical-stage biotechnology company developing an oral small-molecule immune [...]